Cancer Management and Research最新文献

{"title":"The Naples Prognostic Score Exerts a Significant Impact on the Prognosis of Patients Diagnosed with External Auditory Canal Carcinoma After Surgery.","authors":"Xue-Lian Xu, Hao Cheng, Xin-Meng Wu, Jin-Hong Xu","doi":"10.2147/CMAR.S527496","DOIUrl":"https://doi.org/10.2147/CMAR.S527496","url":null,"abstract":"<p><strong>Background: </strong>External auditory canal carcinoma (EACC) is a rare malignant tumor. This study aimed to investigate the influence of the comprehensive index of nutrition- Naples prognostic score (NPS) on the prognosis of EACC patients with surgical resection.</p><p><strong>Methods: </strong>A total of 73 EACC patients with surgical resection were selected from two tertiary medical institutions, and were diagnosed between Sep 2008 and Aug 2019. The univariate and multivariate Cox regression analyses were used to identify the independent prognostic factors for disease-free survival (DFS) and overall survival (OS) for postoperative EACC patients. The prognosis for postoperative EACC patients with varying NPS were displayed by Kaplan-Meier plots.</p><p><strong>Results: </strong>The 3- and 5-year survival rate for EACC patients with surgical resection were 72.6%, 32.9% for DFS, and 76.7%, 52.1% for OS, respectively. The multivariate Cox regression analysis revealed that advanced Pittsburgh stage, perineural invasion, vascular invasion, and higher NPS were identified as independent prognostic factors for DFS. Additionally, advanced Pittsburgh stage, vascular invasion, an ACCI score of 6 or higher, and higher NPS were found to be independent predictors for OS.</p><p><strong>Conclusion: </strong>NPS serves as a crucial predictor of postoperative outcomes in patients with EACC, with higher levels indicating poorer disease-free and overall survival. Additionally, factors such as Pittsburgh stage, perineural and vascular invasion, and ACCI are also significant prognostic indicators.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"985-996"},"PeriodicalIF":2.5,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors and Prognostic Implications in Synchronous Breast-Thyroid Dual Primary Cancers: A Matched Case-Control Study.","authors":"Tao Li, Bin Lu, Yantao Zhang, Peng Zhang, Jun Qi, Yong Sun","doi":"10.2147/CMAR.S505310","DOIUrl":"https://doi.org/10.2147/CMAR.S505310","url":null,"abstract":"<p><strong>Objective: </strong>To characterize the distinct clinicopathological patterns and identify independent risk factors in synchronous breast-thyroid dual primary malignancies (DBTMs), a rare yet clinically significant entity.</p><p><strong>Methods: </strong>In this retrospective case-control study (2019.03-2021.12), 58 DBTM patients were compared with 89 age-matched solitary breast cancer controls. Comprehensive clinicopathological parameters including hormone receptor status and molecular profiles were analyzed. Multivariable logistic regression identified prognostic determinants with 2-year follow-up for recurrence/metastasis and survival outcomes.</p><p><strong>Results: </strong>Statistically significant differences were observed in age, BMI, menopausal status, ER, PR, and HER-2 status between the study and control groups (P < 0.05). During the 2-year follow-up, the study group had 12 cases of recurrence or metastasis and 5 deaths, while the control group had 9 cases of recurrence or metastasis and 2 deaths (P < 0.05). Univariate analysis indicated that age, breast cancer stage, and ER status were associated with overall survival in patients with synchronous primary breast and thyroid cancer. Additionally, age, breast cancer stage, ER status, menopausal status, and a family history of breast cancer were significantly associated with recurrence or metastasis (P < 0.05). Multivariate logistic regression analysis identified age, ER positivity, and a family history of breast cancer as independent risk factors for synchronous primary breast and thyroid cancer (P < 0.05).</p><p><strong>Conclusion: </strong>This first matched case-control analysis reveals that synchronous DBTMs represent a unique clinical subgroup with aggressive biological behavior. The identified triad of young age, ER positivity, and familial predisposition provides a risk stratification framework for dual-cancer screening and targeted surveillance strategies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"997-1004"},"PeriodicalIF":2.5,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression and Diagnostic Value of Nrf2 and p62 in Cervical Squamous Cell Carcinoma and Intraepithelial Lesions.","authors":"Wei Wei, Xingyan Hu, Qing Han","doi":"10.2147/CMAR.S513226","DOIUrl":"https://doi.org/10.2147/CMAR.S513226","url":null,"abstract":"<p><strong>Background: </strong>This study aims to explore the value of Nuclear Transcription Factor Erythroid 2-Related Factor 2 (Nrf2) and the selective autophagy adapter protein p62/Sequestosome 1 (SQSTM1) in diagnosing cervical squamous cell carcinoma (SCC) and squamous intraepithelial lesions (SIL).</p><p><strong>Methods: </strong>Paraffin specimens from 125 cervical SCC patients, 102 low-grade SIL (LSIL) patients, 101 high-grade SIL (HSIL) patients, and 49 patients with benign/reactive cervical squamous epithelium were collected at Yichang Central People's Hospital from 2010 to 2023. Immunohistochemistry was used to detect Nrf2 and p62 expression. Positive expression was defined by visible light yellow, brownish-yellow, or brown cytoplasmic particles. The correlation between the two proteins and their diagnostic value were analyzed.</p><p><strong>Results: </strong>Both Nrf2 and p62 were predominantly localized to the cytoplasm in various cervical lesions. The expression levels of Nrf2 and p62 were significantly higher in LSIL, HSIL, and SCC than in benign/reactive epithelium (all <i>P</i><0.001), and lower in LSIL than in HSIL and SCC (all <i>P</i><0.001). A positive correlation was found between Nrf2 and p62 in all lesion types (all <i>P</i><0.05). ROC analysis indicated that the diagnostic accuracy was enhanced when Nrf2 and p62 were used in combination, as opposed to using either marker individually.</p><p><strong>Conclusion: </strong>Nrf2 and p62 are either not expressed or expressed at low levels in benign/reactive squamous epithelium, with expression increasing in LSIL, and being highest in HSIL and SCC. Both markers show a positive correlation across different cervical lesions, and either Nrf2 or p62 alone can effectively diagnose various cervical lesions, with even better diagnostic outcomes when used in combination.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1005-1013"},"PeriodicalIF":2.5,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of PET/CT Maximal Standardized Uptake Values with Clinicopathologic Parameters of Aggressive Non-Hodgkin's Lymphoma.","authors":"Yingci Li, Dongbo Wu, Mohan Tian","doi":"10.2147/CMAR.S522628","DOIUrl":"10.2147/CMAR.S522628","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the correlation between the maximum standardized uptake value (SUV_max) of positron emission tomography (PET)/computed tomography (CT) scanning imaging with the clinicopathologic parameters of aggressive non-Hodgkin's lymphoma (NHL) and its diagnostic value.</p><p><strong>Methods: </strong>A total of 128 patients with NHL were retrospectively selected. PET/CT examination was performed to calculate SUV_max, and clinicopathological data were collected. Pearson correlation test was used to analyze the correlation between them, and the relevant indicators were detected according to the pathological results. ROC curve was used to analyze the diagnostic value.</p><p><strong>Results: </strong>The level of PET/CT SUV_max was positively correlated with the levels of β2-microglobulin (β2-MG), lactate dehydrogenase (LDH), Ki-67, tumor size and bone marrow infiltration (P<0.05). The PET/CT SUV_max and serum β2-MG, LDH and Ki-67 levels in the aggressive group were significantly higher than those in the indolent group (P<0.05). The AUC of the combined detection of PET/CT SUV_max, β2-MG, LDH and Ki-67 in the diagnosis of aggressive NHL was 0.920, and the combined detection had a high diagnostic value.</p><p><strong>Conclusion: </strong>PET/CT SUV_max was correlated with a variety of clinicopathological parameters. Combined detection of PET/CT SUV_max has high diagnostic value in aggressive NHL.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"975-984"},"PeriodicalIF":2.5,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of PD-L1 Expression with Lymph Node Metastasis and Clinical Stage in Ampulla of Vater Cancer: An Observational Study.","authors":"Andrianto Andrianto, Reno Rudiman, Tommy Ruchimat, Kiki Lukman, Bambang Am Am Setya Sulthana, Andriana Purnama, Alma Wijaya, Etis Primastari, Prapanca Nugraha","doi":"10.2147/CMAR.S513961","DOIUrl":"10.2147/CMAR.S513961","url":null,"abstract":"<p><strong>Background: </strong>Ampulla of Vater cancer is a subtype of periampullary cancer originating from pancreatic ducts and the bile ducts. Immune checkpoint proteins, particularly Programmed Death-Ligand 1 (PD-L1), show a crucial function in influencing cancer progression, tumor microenvironment, and immune evasion. This study investigates the association between PD-L1 expression and clinical characteristics in patients with ampulla of Vater cancer.</p><p><strong>Methods: </strong>A retrospective observational study was carried out at a general hospital in West Java, Indonesia, from July 2019 to June 2024. Forty-four patients diagnosed with ampulla of Vater cancer were included. PD-L1 expression was evaluated using immunohistochemistry, and clinicopathological data were analyzed using chi-square, Mann-Whitney, and independent <i>t</i>-tests.</p><p><strong>Results: </strong>There were 44 research subject. The PD-L1 expression was positive in 59.1% of patients and negatively associated with carcinoembryonic antigen (CEA) levels (p = 0.010). There was a significant association between PD-L1 positivity and lymph node involvement (p = 0.042) and clinical stage (p = 0.017). No significant association was found between PD-L1 expression and age, sex, histopathological grade, or distant metastasis.</p><p><strong>Conclusion: </strong>PD-L1 expression in ampulla of Vater cancer is significantly associated with higher lymph node metastasis and advanced clinical stage but not with age, sex, or tumor differentiation. These findings suggest PD-L1 as a potential prognostic marker and therapeutic target.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"965-974"},"PeriodicalIF":2.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-38 as a Novel Biomarker in Multiple Myeloma Patients: A Prospective Clinical Evaluation.","authors":"Hailan Shen, Ping Zhao, Ju Cao","doi":"10.2147/CMAR.S520722","DOIUrl":"https://doi.org/10.2147/CMAR.S520722","url":null,"abstract":"<p><strong>Introduction: </strong>Multiple myeloma (MM) is a refractory haematological malignancy. Interleukin 38 (IL-38) is a novel cytokine that has attracted significant research in recently years. However, no study has investigated IL-38 expression in MM. This study aims to investigate the expression of IL-38 in MM and to provide valuable insights for clinical treatment and efficacy evaluation.</p><p><strong>Methods: </strong>A total of 241 patients with MM (146 males, 95 females; R-ISS stage I: 111 cases, stage II: 74 cases, stage III: 56 cases) and 50 healthy individuals were included in this study. Medical records were reviewed for staging. Interleukin-1 (IL-1), interleukin-2 receptor (IL-2R), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α) were detected by chemiluminescence method, IL-38 was detected by enzyme-linked immunosorbent assay (ELISA). Immunoglobulins, free light chains (FLC) and β2-microglobulin (β2-MG) were detected by immune nephelometry, and multiple biochemical indicators were detected by automatic biochemical analyzers.</p><p><strong>Results: </strong>Compared with healthy control group, IL-1, IL-2R, IL-8, and TNF-α were elevated in all three stages of MM. In contrast, compared with normal control group, IL-38 was significantly decreased in patients with MM. When the cut-off value of IL-38 was 18.61 pg/mL, the diagnostic efficacy for MM had a sensitivity of 0.8176 and a specificity of 0.9000.</p><p><strong>Discussion: </strong>IL-38 exhibited decrease in MM patients (<i>p</i><0.0001). It also showed a gradual increase with disease improvement after effective treatment, IL-38 may be a potential biomarker for the diagnosis and prognostic assessment of MM.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"955-964"},"PeriodicalIF":2.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Nomogram Based on Fibrinogen-to-Neutrophil Ratio as a Novel Predictor of Lymph Node Metastasis in Patients with Cervical Cancer and Type 2 Diabetes Mellitus.","authors":"Hongying Kuang, Dongxia Yang, Ruoyao Lin, Yaling Tang, Yongli Luo, Shuwen Wang, Tingting Xia, Ge Lou, Hong Chen","doi":"10.2147/CMAR.S510815","DOIUrl":"https://doi.org/10.2147/CMAR.S510815","url":null,"abstract":"<p><strong>Background: </strong>The rising incidence of cervical cancer among individuals with diabetes is a matter of significant concern, presenting profound implications for the health status and quality of life worldwide. In patients diagnosed with early-stage cervical cancer, the extent of lymph node involvement has emerged as a critical prognostic factor influencing recurrence risk and survival outcomes. Therefore, the precise prediction of pelvic lymph node metastasis is essential for an accurate assessment of prognosis. The preoperative identification of lymph node metastasis constitutes a pivotal element in the formulation of personalized treatment strategies. It has been demonstrated that inflammatory markers such as neutrophils, lymphocytes, and fibrinogen significantly contribute to cancer progression and prognostic evaluations. In this regard, we propose the fibrinogen-to-neutrophil ratio (FNR) as an innovative and promising biomarker for evaluating pelvic lymph node metastasis in cervical cancer patients with type 2 diabetes.</p><p><strong>Methods: </strong>The study was conducted on 141 patients diagnosed with cervical cancer and concomitant type 2 diabetes, who were treated at the First Affiliated Hospital of Xiamen University. The patients were randomly divided into a training set (n=98) and a validation set (n=43), with a ratio of 7:3. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors, and a prognostic model was established based on these findings. The model's effectiveness was evaluated.</p><p><strong>Results: </strong>A nomogram that integrates multiple factors, including FNR, triglycerides, maximum diameter, and total protein, demonstrates superior potential in predicting pelvic lymph node metastasis in patients with type 2 diabetes and cervical cancer, compared to the use of a single biomarker.</p><p><strong>Conclusion: </strong>As a comprehensive biomarker, FNR shows significant potential in offering a more thorough and reliable approach for identifying cervical cancer patients with diabetes who are at an elevated risk of lymph node metastasis.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"933-954"},"PeriodicalIF":2.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Machine Learning Model for Predicting Breast Cancer Recurrence and Supporting Personalized Treatment Decisions Through Comprehensive Feature Selection and Explainable Ensemble Learning.","authors":"Tsair-Fwu Lee, Jun-Ping Shiau, Chia-Hui Chen, Wen-Ping Yun, Cheng-Shie Wuu, Yu-Jie Huang, Shyh-An Yeh, Hui-Chun Chen, Pei-Ju Chao","doi":"10.2147/CMAR.S514693","DOIUrl":"https://doi.org/10.2147/CMAR.S514693","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates the efficiency of a machine learning model integrating least absolute shrinkage and selection operator (LASSO) feature selection with ensemble learning in predicting recurrence risk and supporting personalized treatment decisions in breast cancer patients.</p><p><strong>Materials and methods: </strong>Clinical data from 1,131 breast cancer patients (1,056 nonrecurrent and 75 recurrent) were collected from Kaohsiung Medical University Hospital's electronic health record system. After preprocessing and standardization, LASSO was applied for feature selection. An ensemble learning model was developed based on multiple machine learning algorithms, with SHAP (Shapley additive explanations) used for interpretability.</p><p><strong>Results: </strong>The ensemble model achieved an AUC of 0.817, outperforming the best single model (AUC 0.711), demonstrating improved predictive accuracy and stability. LASSO identified six key predictors: regional lymph node positivity, ER status, Ki-67, lymphovascular invasion, tumor size, and age at diagnosis. SHAP analysis enhanced transparency by quantifying the contribution of each feature to recurrence risk, improving clinical understanding.</p><p><strong>Conclusion: </strong>This LASSO-enhanced ensemble model significantly improves the accuracy and interpretability of breast cancer recurrence prediction. By identifying individualized recurrence risks through SHAP analysis, the model supports more precise, data-driven clinical decision-making. These findings demonstrate its potential as a clinical decision support tool for guiding personalized treatment strategies, contributing to more effective breast cancer management.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"917-932"},"PeriodicalIF":2.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.","authors":"Jiaran Zhang, Huichun Tian, Lili Mao, Caili Li, Xiaoting Wei, Junjie Gu, Xuan Wang, Li Zhou, Bin Lian, Bixia Tang, Xieqiao Yan, Siming Li, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Jun Guo, Lu Si","doi":"10.2147/CMAR.S520937","DOIUrl":"https://doi.org/10.2147/CMAR.S520937","url":null,"abstract":"<p><strong>Purpose: </strong>The combination of programmed cell death-1 (PD-1) blockade camrelizumab plus apatinib (an antiangiogenic agent) and temozolomide has displayed promising therapeutic effects in patients with advanced acral melanoma (AM) in a non-randomized Phase II clinical trial (NCT04397770). The aim of this retrospective study was to evaluate the efficacy and safety of the triplet regimen for advanced AM in the real-world setting.</p><p><strong>Methods: </strong>The data of patients with advanced AM who received anti-PD-1 antibody plus apatinib and temozolomide at Peking University Cancer Hospital and Institute between September 2019 and December 2023 were analyzed. The primary endpoint was the overall response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR), and treatment-related adverse events (TRAEs).</p><p><strong>Results: </strong>Overall, 250 patients were eligible for the analysis. The ORR was 38.1% and the DCR was 92.2%. The median PFS, OS, and DOR were 8.5, 18.0, and 13.2 months, respectively. When used as first-line treatment, the ORR was 48.1%, the median PFS was 12.0 months, and the median OS was 24.8 months. The number of lines of therapy (≥2 lines), elevated lactate dehydrogenase, and presence of brain or liver metastasis were negative predictors of survival. Overall, 92.4% and 45.2% of the patients experienced any-grade and grade 3-4 TRAEs, respectively.</p><p><strong>Conclusion: </strong>This study provides real-world evidence that support the effectiveness and safety of combined anti-PD-1 antibody, apatinib and temozolomide for treating advanced AM, demonstrating a considerable ORR and prolonged survival, as well as acceptable tolerability.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"905-916"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence Prediction by Multi-Omics in the Patient with Colorectal Peritoneal Metastases After Cytoreductive Surgery: A Prospective Biomarker Study.","authors":"Chao Chen, Zhiyuan Gong, Zhiwei Zhang, Haochen Gu, Akao Zhu, Di Peng, Bing Li, Jian Wang, Yeting Hu, Da Wang, Lifeng Sun","doi":"10.2147/CMAR.S519094","DOIUrl":"https://doi.org/10.2147/CMAR.S519094","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer with peritoneal metastases (CRCPM) exhibits high recurrence post-cytoreductive surgery (CRS). This study evaluated tumor tissue biomarkers and combined circulating tumor DNA (ctDNA) and methylation analysis via ultra-deep next-generation sequencing (NGS) for recurrence prediction.</p><p><strong>Methods: </strong>CRCPM patients undergoing surgery were enrolled (n=21). Blood samples was collected at preoperative and postoperative, and tumor and adjacent tissues were collected. NGS assessed ctDNA and methylation in blood samples, while tumor mutations and methylation were analyzed in tumor. Recurrence was determined via imaging. Outcomes included progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>Of 17 patients with paired pre-/postoperative ctDNA testing, preoperative ctDNA levels were higher in those with extraperitoneal metastases versus peritoneal-only disease (0.1064 vs 0.0037). Postoperative ctDNA positivity correlated with 100% peritoneal recurrence. ctDNA-positive subgroups showed shorter PFS (HR=2.5; 95% CI:1.6-6.6). Patients persistently ctDNA-negative pre-/postoperatively had improved PFS versus those with positivity (HR=5.07; 95% CI:0.53-48.38). ctDNA methylation positivity was observed in all extraperitoneal metastasis cases and 70% of peritoneal-only cases. Baseline methylation positivity predicted worse OS overall and in peritoneal-only subgroups. Postoperative dual negativity for ctDNA and methylation correlated with better OS. Tumor mutations in EPHB1 (<i>P</i> = 0.012), ARFRP1 (<i>P</i> = 0.048), and ATR (<i>P</i> = 0.048) were significantly associated with PFS.</p><p><strong>Conclusion: </strong>Dynamic ctDNA and methylation monitoring, and tumor mutation profiling, may serve as sensitive biomarkers for early recurrence detection in CRCPM underwent CRS. These tools could enhance recurrence prediction and guide clinical management.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"893-904"},"PeriodicalIF":2.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}